Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Frontiers in Immunology|June 12, 2025
Efficiency of cell-based assays in detecting AChR antibodies in myasthenia gravis sera with low antibody concentrations as determined by radioimmunoprecipitation assayJohn S Tzartos, Aigli G Vakrakou, Katerina Karagiorgou, et al.
Journal of Neuroimmunology|October 30, 2025
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Practical recommendations for diagnosis and managementElia Sechi, Matteo Gastaldi, Rosa Cortese, et al.
Epilepsia|August 6, 2025
The gut microbiome associated with LGI1-antibody encephalitisEdmund Gilbert, Sophie Binks, Valentina Damato, et al.
European Journal of Neurology|October 28, 2021
Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of AtaxiaValentina Damato, Claudia Papi, Gregorio Spagni, et al.
Annals of the New York Academy of Sciences|January 30, 2018
Serological and experimental studies in different forms of myasthenia gravisAngela Vincent, Saif Huda, Michelangelo Cao, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|September 19, 2024
Clinical Course of Neurologic Adverse Events Associated With Immune Checkpoint Inhibitors: Focus on Chronic ToxicitiesSimone Rossi, Antonio Farina, Antonio Malvaso, et al.
Research Square|March 27, 2026
Engineered Bi-Specific AChR CAAR T Cells for Selective Elimination of Myasthenia Gravis B CellsNiels von Wardenburg, Gregorio Spagni, S Reincke, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 21, 2025
Therapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathologyAlexandra C Bayer, Liliana M Sanmarco, Alex Pellerin, et al.
Neurology|May 26, 2026
Comparative Study of Sporadic and Immune Checkpoint Inhibitor-Related Forms of Myasthenia Gravis-Myositis Overlap SyndromeAntonio Lauletta, Elena Rossini, Francesca Beretta, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 6, 2022
Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disordersValentina Damato, Jakob Theorell, Adam Al-Diwani, et al.
Pageof 7